Ironshore Pharmaceuticals and Development, Inc

Quick facts

Phase 3 pipeline

• HLD200 · Oncology
  HLD200 is a histone deacetylase (HDAC) inhibitor that modulates gene expression by blocking HDAC enzymes.

Phase 2 pipeline

• HLD100

Phase 1 pipeline

• HLD100-B
• HLD100-C
• HLD100-E

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Ironshore Pharmaceuticals and Development, Inc portfolio CI brief
• Ironshore Pharmaceuticals and Development, Inc pipeline updates RSS